In 14 NSCLC patients treated with nivolumab, there was a significant association between early progress and higher kyn/trp ratio (indicating higher IDO activity), suggesting the possibility of combinational treatment of nivolumab and IDO inhibitor [58]. Here, IDO1 is linked to non-small cell lung carcinoma.